Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 145 Parkinson Disease 4, Autosomal Dominant Lewy Body 121 Melanoma 84 Squamous Cell Carcinoma of Head and Neck 56 Neoplasms 44 Breast Neoplasms 41 Stomach Neoplasms 39 Colorectal Neoplasms 39 Triple Negative Breast Neoplasms 37 Neoplasm Metastasis 36 Carcinoma, Renal Cell 36 Ovarian Neoplasms 30 Lung Neoplasms 30 Head and Neck Neoplasms 29 Urinary Bladder Neoplasms 28 Carcinoma, Transitional Cell 26 Carcinoma, Hepatocellular 26 Pancreatic Neoplasms 23 Esophageal Neoplasms 20 Endometrial Neoplasms 16 Recurrence 15 Prostatic Neoplasms 15 Multiple Myeloma 15 Fallopian Tube Neoplasms 15 Carcinoma 14 Sarcoma 13 Lymphoma, Large B-Cell, Diffuse 13 Small Cell Lung Carcinoma 12 Lymphoma, Follicular 12 Lymphoma, Non-Hodgkin 11

Interventions

Fulvestrant 4 Letrozole 2 Goserelin 2 Docetaxel 2 Dasatinib 2 vandetanib 1 sonidegib 1 pembrolizumab 1 palbociclib 1 olaparib 1 exemestane 1 cediranib 1 Lead 1 Gemcitabine 1 Everolimus 1 Capecitabine 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Advanced Breast Cancer × pembrolizumab × Clear all

NCT03025880 2023-04-03

PANGEA

Spanish Breast Cancer Research Group

Phase 2 Completed

36 enrolled 28 charts

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡